PI3Kgamma Inhibitor Attenuates Immunosuppressive Effect of Poly( l ‐Glutamic Acid)‐Combretastatin A4 Conjugate in Metastatic Breast Cancer
出版年份 2019 全文链接
标题
PI3Kgamma Inhibitor Attenuates Immunosuppressive Effect of Poly(
l
‐Glutamic Acid)‐Combretastatin A4 Conjugate in Metastatic Breast Cancer
作者
关键词
-
出版物
Advanced Science
Volume -, Issue -, Pages 1900327
出版商
Wiley
发表日期
2019-04-18
DOI
10.1002/advs.201900327
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Selectively Potentiating Hypoxia Levels by Combretastatin A4 Nanomedicine: Toward Highly Enhanced Hypoxia-Activated Prodrug Tirapazamine Therapy for Metastatic Tumors
- (2019) Shengcai Yang et al. ADVANCED MATERIALS
- Randomized Trial Comparing Resection of Primary Tumor with No Surgery in Stage IV Breast Cancer at Presentation: Protocol MF07-01
- (2018) Atilla Soran et al. ANNALS OF SURGICAL ONCOLOGY
- Hypoxic tumor-derived exosomal miR-301a mediates M2 macrophage polarization via PTEN/PI3Kγ to promote pancreatic cancer metastasis
- (2018) Xiaofeng Wang et al. CANCER RESEARCH
- Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa
- (2018) Kabir A. Khan et al. Nature Reviews Clinical Oncology
- The homeobox protein VentX reverts immune suppression in the tumor microenvironment
- (2018) Yi Le et al. Nature Communications
- The impact of PI3K inhibitors on breast cancer cell and its tumor microenvironment
- (2018) Hanjiao Qin et al. PeerJ
- Photosensitizer Micelles Together with IDO Inhibitor Enhance Cancer Photothermal Therapy and Immunotherapy
- (2018) Jinrong Peng et al. Advanced Science
- Contribution to Tumor Angiogenesis From Innate Immune Cells Within the Tumor Microenvironment: Implications for Immunotherapy
- (2018) Adriana Albini et al. Frontiers in Immunology
- Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors
- (2018) Asha Nayak-Kapoor et al. Journal for ImmunoTherapy of Cancer
- Binary Cooperative Prodrug Nanoparticles Improve Immunotherapy by Synergistically Modulating Immune Tumor Microenvironment
- (2018) Bing Feng et al. ADVANCED MATERIALS
- Immune Checkpoint Inhibition Overcomes ADCP-Induced Immunosuppression by Macrophages
- (2018) Shicheng Su et al. CELL
- Exploiting the cancer niche: Tumor-associated macrophages and hypoxia as promising synergistic targets for nano-based therapy
- (2017) Vera L. Silva et al. JOURNAL OF CONTROLLED RELEASE
- T-cell invigoration to tumour burden ratio associated with anti-PD-1 response
- (2017) Alexander C. Huang et al. NATURE
- Tumour-associated macrophages as treatment targets in oncology
- (2017) Alberto Mantovani et al. Nature Reviews Clinical Oncology
- Leveraging Physiology for Precision Drug Delivery
- (2017) Wujin Sun et al. PHYSIOLOGICAL REVIEWS
- Tumor Neovasculature-Targeted APRPG-PEG-PDLLA/MPEG-PDLLA Mixed Micelle Loading Combretastatin A-4 for Breast Cancer Therapy
- (2017) Ying Hao et al. ACS Biomaterials-Science & Engineering
- Tumor Neovasculature-Targeted APRPG-PEG-PDLLA/MPEG-PDLLA Mixed Micelle Loading Combretastatin A-4 for Breast Cancer Therapy
- (2017) Ying Hao et al. ACS Biomaterials Science & Engineering
- The Multifaceted Role of Perivascular Macrophages in Tumors
- (2016) Claire E. Lewis et al. CANCER CELL
- Immune suppressive mechanisms in the tumor microenvironment
- (2016) David H Munn et al. CURRENT OPINION IN IMMUNOLOGY
- The impact of hypoxia on tumor-associated macrophages
- (2016) Anne-Theres Henze et al. JOURNAL OF CLINICAL INVESTIGATION
- Antiangiogenic therapy in oncology: current status and future directions
- (2016) Gordon C Jayson et al. LANCET
- Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells
- (2016) Olivier De Henau et al. NATURE
- PI3Kγ is a molecular switch that controls immune suppression
- (2016) Megan M. Kaneda et al. NATURE
- The ever-expanding role of HIF in tumour and stromal biology
- (2016) Edward L. LaGory et al. NATURE CELL BIOLOGY
- An immunostimulatory dual-functional nanocarrier that improves cancer immunochemotherapy
- (2016) Yichao Chen et al. Nature Communications
- Targeting PI3K in Cancer: Impact on Tumor Cells, Their Protective Stroma, Angiogenesis, and Immunotherapy
- (2016) K. Okkenhaug et al. Cancer Discovery
- Doxorubicin-loaded polysaccharide nanoparticles suppress the growth of murine colorectal carcinoma and inhibit the metastasis of murine mammary carcinoma in rodent models
- (2015) Mingqiang Li et al. BIOMATERIALS
- Phase III Trial Evaluating the Addition of Bevacizumab to Endocrine Therapy As First-Line Treatment for Advanced Breast Cancer: The Letrozole/Fulvestrant and Avastin (LEA) Study
- (2015) Miguel Martín et al. JOURNAL OF CLINICAL ONCOLOGY
- Pharmacokinetics, biodistribution and in vivo efficacy of cisplatin loaded poly(l-glutamic acid)-g-methoxy poly(ethylene glycol) complex nanoparticles for tumor therapy
- (2015) Haiyang Yu et al. JOURNAL OF CONTROLLED RELEASE
- Current mechanistic insights into the roles of matrix metalloproteinases in tumour invasion and metastasis
- (2015) Gordon T Brown et al. JOURNAL OF PATHOLOGY
- Clinical and molecular complexity of breast cancer metastases
- (2015) Siker Kimbung et al. SEMINARS IN CANCER BIOLOGY
- A Macrophage-Dominant PI3K Isoform Controls Hypoxia-Induced HIF1α and HIF2α Stability and Tumor Growth, Angiogenesis, and Metastasis
- (2014) Shweta Joshi et al. MOLECULAR CANCER RESEARCH
- Induction of hypoxia by vascular disrupting agents and the significance for their combination with radiation therapy
- (2013) Ane B. Iversen et al. ACTA ONCOLOGICA
- AVEREL: A Randomized Phase III Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER2-Positive Locally Recurrent/Metastatic Breast Cancer
- (2013) Luca Gianni et al. JOURNAL OF CLINICAL ONCOLOGY
- PI3-Kinase γ Promotes Rap1a-Mediated Activation of Myeloid Cell Integrin α4β1, Leading to Tumor Inflammation and Growth
- (2013) Michael C. Schmid et al. PLoS One
- Receptor Tyrosine Kinases and TLR/IL1Rs Unexpectedly Activate Myeloid Cell PI3Kγ, A Single Convergent Point Promoting Tumor Inflammation and Progression
- (2011) Michael C. Schmid et al. CANCER CELL
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- A perspective on vascular disrupting agents that interact with tubulin: preclinical tumor imaging and biological assessment
- (2011) Ralph P. Mason et al. Integrative Biology
- TIE2-expressing macrophages limit the therapeutic efficacy of the vascular-disrupting agent combretastatin A4 phosphate in mice
- (2011) Abigail F. Welford et al. JOURNAL OF CLINICAL INVESTIGATION
- Antiangiogenic therapy: impact on invasion, disease progression and metastasis
- (2011) John M. L. Ebos et al. Nature Reviews Clinical Oncology
- Contribution of Granulocyte Colony-Stimulating Factor to the Acute Mobilization of Endothelial Precursor Cells by Vascular Disrupting Agents
- (2009) Y. Shaked et al. CANCER RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started